Article

Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile.

Sanofi-Aventis, B.P.110, 92225 Bagneux Cedex, France.
Neuroscience (Impact Factor: 3.33). 08/2008; 156(2):353-64. DOI: 10.1016/j.neuroscience.2008.07.011
Source: PubMed

ABSTRACT SR58611A is a selective beta(3)-adrenoceptor (Adrb3) agonist which has demonstrated antidepressant and anxiolytic properties in rodents. The present study confirmed the detection of Adrb3 mRNA transcript in rodent brain sub-regions and evaluated the effect of SR58611A on serotonergic and noradrenergic transmission in rats and mice in an attempt to elucidate the mechanism(s) underlying these properties. SR58611A (3 and 10 mg/kg, p.o.) increased the synthesis of 5-HT and tryptophan (Trp) levels in several rodent brain areas (cortex, hippocampus, hypothalamus, striatum). Moreover, SR58611A (10 mg/kg, p.o.) increased the release of 5-HT assessed by in vivo microdialysis in rat prefrontal cortex. Systemic (3 mg/kg, i.v.) or chronic administration of SR58611A (10 mg/kg, p.o.), in contrast to fluoxetine (15 mg/kg, p.o.), did not modify the activity of serotonergic neurons in the rat dorsal raphe nucleus. The increase in 5-HT synthesis induced by SR58611A was not observed in Adrb3s knockout mice, suggesting a selective involvement of Adrb3s in this effect. SR58611A (3 and 10 mg/kg, p.o.) did not modify norepinephrine synthesis and metabolism but increased its release in rat brain. Repeated administration of SR58611A (10 mg/kg, p.o.) did not modify basal norepinephrine release in rat prefrontal cortex whereas it prevented its tail-pinch stress-induced enhancement similarly to reboxetine (15 mg/kg, p.o.). Finally SR58611A increased the firing rate of noradrenergic neurons in the rat locus coeruleus following systemic (3 mg/kg, i.v.) or local (0.01 and 1 microM) but not chronic (10 mg/kg, p.o.) administration. These results suggest that the anxiolytic- and antidepressant-like activities of SR58611A involve an increase of brain serotonergic and noradrenergic neurotransmissions, triggered by activation of Adrb3s.

0 Followers
 · 
179 Views
  • Source
    • "The interaction of β 3-ARs activity with other neurotransmissions which has been shown to play important roles in depression and anxiety, has further strengthened the previously described theories . In fact, the activation of the β3-AR has been suggested to increase brain serotonin synthesis (Consoli et al., 2007) whereas amibegron anxiolytic-and antidepressant-like activities might be mediated, at least in part, via the increase of brain serotonergic and noradrenergic neurotransmissions (Claustre et al., 2008). Finally, it was proposed that neuronal production can be increased via the activation of both neurogenic precursors and stem cells through β3- ARs and points out a new therapeutic target for novel antidepressants (Jhaveri et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adrenergic receptors belong to the family of the G protein coupled receptors that represent important targets in the modern pharmacotherapies. Studies on different physiological and pathophysiological prop-erties of the adrenergic system have led to novel evidences and theories that suggest novel possible targeting of such system in a variety of pathologies and disorders, even beyond the classical known therapeutic possibilities. Herein, those advances have been illustrated with selected concepts and different ex-amples. Furthermore, we illustrated the applications and the therapeutic implications that such findings and advances might have in the contexts of experimental pharmacology, therapeutics and clinic. We hope that the content of this work will guide researches devoted to the adrenergic aspects that combine neu-rosciences with pharmacology.
    Neuropeptides 11/2014; 49. DOI:10.1016/j.npep.2014.11.003 · 2.55 Impact Factor
  • Source
    • "In addition, these data provide the first evidence of a behavioral role for LPCS interneurons, as the selective enhancement of LPCS synapses was sufficient to produce robust decreases in anxiety-related behaviors. It should, however, be noted that b3-AR mRNA has been detected in many other brain regions and b3-AR activation can increase 5-HT transmission , possibly through a peripheral mechanism, as well as NE neurotransmitter levels through a direct increase in the firing rate of LC neurons (Claustre et al, 2008). Therefore, it seems likely that b3-ARs in multiple brain regions may be important in the regulation of anxiety-like behaviors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Norepinephrine (NE) is known to play an integral role in the neurobiological response to stress. Exposure to stressful stimuli increases NE levels in brain regions that regulate stress and anxiety, like the basolateral amygdala (BLA). NE is thought to increase excitability in these areas through alpha- and beta-adrenoceptors (ARs), leading to increased anxiety. Surprisingly, recent studies have shown that systemic beta 3-AR agonist administration decreases anxiety-like behaviors, suggesting that beta 3-ARs may inhibit excitability in anxiety-related brain regions. Therefore, in this study we integrated electrophysiological and behavioral approaches to test the hypothesis that the anxiolytic effects of beta 3-AR agonists may be mediated by an increase in BLA GABAergic inhibition. We examined the effect of a selective beta 3-AR agonist, BRL37344 (BRL), on GABAergic synapses arising from local circuit interneurons and inhibitory synapses originating from a recently described population of cells called lateral paracapsular (LPCS) interneurons. Surprisingly, BRL selectively enhanced LPCS-evoked inhibitory postsynaptic currents (eIPSCs) with no effect on local GABAergic inhibition. BRL also had no effect on glutamatergic synaptic excitation within the BLA. BRL potentiation of LPCS eIPSCs was blocked by the selective beta 3-AR antagonist, SR59230A, or by intracellular dialysis of Rp-CAMPS (cAMP-dependent protein kinase inhibitor), and this enhancement was not associated with any changes in spontaneous IPSCs or LPCS paired-pulse ratio. BRL also increased the amplitude of unitary LPCS IPSCs (uIPSCs) with no effect on uIPSC failure rate. Finally, bilateral BLA microinjection of BRL reduced anxiety-like behaviors in an open-field assay and the elevated plus-maze. Collectively, these data suggest that beta 3-AR activation selectively enhances LPCS, but not local, BLA GABAergic synapses, and that increases in LPCS-mediated inhibition may contribute to the anxiolytic profile of beta 3-AR agonists.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 08/2010; 35(9):1886-96. DOI:10.1038/npp.2010.59 · 7.83 Impact Factor
  • Source
    • "demand reagents for GPR40 (Assay ID: Mm00809442 s1) as previously described (Claustre et al., 2008). Adult male mice in the N3 generation (87.5% C57BL/6J and 12.5% 129/SvEv) were used in the current study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The free fatty acid (FFA) receptor GPR40, expressed by pancreatic beta-cells, may be responsible for insulin release following beta(3) adrenoceptor (Adrb3) activation. To test this hypothesis, we first studied the effects of Adrb3 agonists SR58611A and CL316,243 in GPR40 knockout (GPR40(-/-)) mice. Both drugs increased blood FFA levels in wild-type (GPR40(+/+)) and GPR40(-/-) mice, indicating that lipolysis is not GPR40-dependent. However, the magnitude of the insulin response after agonist treatment was decreased by approximately 50% in GPR40(-/-) mice. Analysis of the time-course revealed that the change in FFAs (5-10 min post-treatment) in response to SR58611A preceded insulin secretion (10-15 min post-treatment). While reduced by agonist treatment, glucose levels in GPR40(-/-) mice remained significantly higher than in GPR40(+/+) mice. Energy expenditure, food intake, or body weight was not affected in GPR40(-/-) mice, whereas SR58611A increased energy metabolism. Furthermore, CL316,243 did not potentiate glucose-stimulated insulin secretion in isolated mouse islets or activate a cAMP reporter in transgenic mice. Our data indicate that insulin secretion, a secondary event following stimulation of Adrb3 receptors, is partially mediated by GPR40 and suggest that GPR40 is integral to the anti-diabetes effects of Adrb3 agonists.
    Molecular and Cellular Endocrinology 04/2010; 325(1-2):18-25. DOI:10.1016/j.mce.2010.04.014 · 4.24 Impact Factor
Show more